Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/30/2025

Upper Gastrointestinal Bleeding Management

Risk Assessment and Stratification

  • The American College of Physicians recommends using the Glasgow-Blatchford Score (GBS) to identify patients with upper gastrointestinal bleeding (UGIB) who are at very low risk for rebleeding or mortality, with a score of ≤1 indicating patients who may not require hospitalization or inpatient endoscopy 1, 2
  • The GBS calculation includes blood urea nitrogen (BUN), hemoglobin, systolic blood pressure, heart rate, presence of melena or syncope, and history of liver disease or heart failure, with the following table summarizing the score calculation:
Variable Points
Hemoglobin (g/L) -1 for ≥120, -2 for 100-119, -3 for 80-99, -4 for <80
Blood urea (mmol/L) -1 for ≥6.5, -2 for 5-6.4, -3 for 3.5-4.9, -4 for <3.5
Pulse (bpm) -1 for ≥100, -2 for 80-99, -3 for <80
Systolic blood pressure (mmHg) -1 for ≥100, -2 for 80-99, -3 for <80
Syncope or melena -2
Hepatic disease or cardiac failure -2
  • Patients with a GBS of ≤1 can be safely managed as outpatients, with a negative predictive value of 96.6% for adverse outcomes 1, 2
  • The GBS is superior to the Rockall Score in predicting need for transfusion (AUROC 0.944 vs. 0.756) and is recommended over the AIMS65 score for identifying patients at very low risk for adverse outcomes 1

Guideline Recommendations

  • The American College of Physicians recommends hospitalization for patients with a GBS of 2-6, with endoscopy within 24 hours and close monitoring for clinical deterioration 1
  • Patients with a GBS of ≥7 require immediate hospitalization, aggressive resuscitation, urgent endoscopy (within 24 hours), and consideration for ICU admission for very high scores 1, 3
  • Endoscopy should be performed within 24 hours of presentation for most patients with upper gastrointestinal bleeding (UGIB), with a strong recommendation and high strength of evidence from the American College of Gastroenterology 1, 3

Endoscopic Therapy and Medical Management

  • Endoscopic therapy with thermocoagulation, sclerosant injection, or hemoclips is recommended for high-risk stigmata (active bleeding, visible vessel, adherent clot), with a strong recommendation and high strength of evidence from the American College of Gastroenterology 1
  • Proton pump inhibitor (PPI) therapy via IV loading dose followed by continuous infusion is recommended after successful endoscopic therapy for high-risk stigmata, with a strong recommendation and high strength of evidence from the American College of Gastroenterology 1
  • Patients with low-risk stigmata (flat spot or clean base) do not routinely require endoscopic therapy, with a moderate strength of evidence from the American College of Gastroenterology 1
  • Aggressive fluid resuscitation should be performed to maintain hemodynamic stability, and blood transfusion should be considered for hemoglobin ≤70 g/L (or higher threshold based on comorbidities), with a moderate to high strength of evidence 3

Implementation and Limitations

  • The GBS should be used in conjunction with clinical judgment, especially for patients with borderline scores 1
  • Clear protocols should be established for outpatient follow-up for discharged low-risk patients 1
  • Over-reliance on a single cutoff value and failure to consider comorbidities can lead to inappropriate discharge or admission decisions 1